Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model

S Modok¹, R Scott¹, RA Alderden², MD Hall², HR Mellor¹, S Bohic³, T Roose⁴, TW Hambley² and R Callaghan*,¹

¹Oxford Drug Resistance Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Level 4, The John Radcliffe Hospital, Oxford OX3 9DU, UK; ²Centre for Heavy Metals Research, School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia; ³ESRF, Micro-Fluorescence/Imaging/Diffraction – ID22, 6, rue Jules Horowitz, BP 220, F-38043 Grenoble Cedex, France; ⁴Oxford Centre for Industrial and Applied Mathematics and Centre for Mathematical Biology, Mathematical Institute, University of Oxford, 24-29 St Giles’, Oxford OX1 3LB, UK

Four-coordinate (Pt(II)) platinum-based anticancer drugs are widely used in primary or palliative chemotherapy and produce considerable efficacy in certain clinical applications, for example testicular cancer. However, in many cancers the Pt(II) drugs are beset by poor efficacy mainly due to suboptimal pharmacokinetic properties. Consequently, the six-coordinate (Pt(IV)) class of Pt drugs were developed to improve platinum efficacy by (i) increasing stability, (ii) reducing reactivity, (iii) increasing lipophilicity, and (iv) nuclear targeting. However, comparatively little information is available on the pharmacokinetic properties of these compounds within solid tumour tissue. In the present study, the distribution and fluxes of [¹³C]-labelled [PtCl₂(OH)₂(en)] (where en stands for ethane-1,2-diamine) and cis,trans-[PtCl₂(OH)₂(en)] drugs were determined in the multicell layer (MCL) tumour model comprising colon cancer cells. Flux data were analysed by mathematical modelling of drug diffusion and cellular uptake in the transport system. The flux of the Pt(IV) compound through the MCL was not significantly different to that of the Pt(II) drug nor were the diffusion coefficient or tissue uptake; the latter confirmed with elemental imaging analysis by synchrotron radiation induced X-ray emission. However, the flux of the Pt(IV) through the MCL was increased by hydrostatic pressure, thereby demonstrating the potential to target cancer cells further away from the vessels with six-coordinate platinum drugs.

British Journal of Cancer (2007) 97, 194–200. doi:10.1038/sj.bjc.6603854 www.bjcancer.com
Published online 19 June 2007
© 2007 Cancer Research UK

Keywords: cisplatin; convection; diffusion; drug delivery; multicell layer; 3D tumour model

Platinum drug complexes have been in clinical use for three decades and their greatest curative potential is exhibited towards certain subtypes of testicular cancer. The Pt complexes are widely used in cancer chemotherapy but unfortunately their efficacy is limited against the majority of malignancies. The reasons for the failure of this important class of chemotherapeutic agent are a combination of cellular drug resistance, toxicity and poor whole-body or cellular pharmacokinetic profiles (Wang and Lippard, 2005). Cellular resistance to Pt drugs is largely attributed to upregulation of DNA repair pathways, low intracellular accumulation and inactivation by thiol-containing reductants such as glutathione and metallothionein. Toxicity of cisplatin and its four-coordinate derivatives is due to inherently high reactivity, which leads to premature adduct formation with nucleophilic groups on macromolecules (Kartalou and Essigmann, 2001). The reactivity results from ‘aquation’ caused by the exchange of Cl⁻ moieties for OH⁻ in a low chloride environment, such as that in the intracellular milieu. The activation will ultimately manifest as the side-effect profile in addition to ensuring that only a minor fraction of the plasma platinum dose will be available to form adducts with the DNA (Lindauer and Holler, 1996). Platinum can exist in the oxidation states II and IV, and the presence of axial ligands in the six-coordinate Pt(IV) complexes has generated a series of compounds with considerably lower ‘aquation’ rates (Dolman et al., 2002). The resultant increased stability and reduced covalent binding to serum proteins (Dolman et al., 2002), facilitates delivery of Pt(IV) drug to cancer cells at effective concentrations.

The efficacy of Pt(II) complexes is severely limited due to poor cellular uptake. The main pathway for intracellular accumulation of Pt drugs is thought to be passive diffusion through the plasma membrane (Siddik, 2002), although the Ctr1 copper importer (Holzer et al., 2004) and the copper export pump ATP7B (Katano et al., 2004) have also been implicated. The introduction of hydrophobic axial ligands in Pt(IV) complexes was thought to provide a strategy to facilitate passive diffusion into cancer cells. Unfortunately, the correlation between lipophilicity and cellular uptake was weak for Pt(IV) compounds (Hall et al., 2004a), although among a range of Pt(IV) compounds cis,trans-[PtCl₂(OH)₂(en)] (where en stands for ethane-1,2-diamine) was the least lipophilic (log Pₐqₑ₃: −2.78) and had the lowest cellular uptake. In contrast, there was a better correlation between the redox potential and uptake of these compounds. This finding has generated a model, which proposes that the Pt(IV) drug exists in a dynamic equilibrium across the cell membrane and that the preferable rate of intracellular ‘aquation’ and subsequent reactivity effectively traps the drug inside the cell (Hall et al., 2004b).
Despite the many advantageous features of Pt(IV) complexes that have been demonstrated in monolayer cultures of cancer cells, few of this class of drug have entered clinical trials. A possible explanation for this lack of translation may be the complexity of solid tumours in vivo, relative to the in vitro experimental system. Tumours in vivo represent complex three-dimensional cellular organisations with a characteristically harsh microenvironment comprising high cell density, low pH, toxic metabolites, low oxygenation and elevated interstitial pressure. Few studies have systematically examined the impact of these and other factors on the efficacy of Pt(IV) complexes in solid tumours or provided information on the distribution, diffusivity and flux of Pt(IV) complexes through a solid tumour. It is known that the driving force for passive diffusion through the plasma membrane is the concentration gradient of the platinum compound. Hence increased penetration of Pt(IV) complexes into tumour tissues, a higher local drug concentration and rapid intracellular aquation may significantly impact on the delivery of platinum compounds to nuclear DNA. Given the complexity of tumour architecture and biology there are many factors contributing to poor success; penetration and uptake are the first such factors that need to be overcome. Ensuring efficient delivery and uptake do not guarantee efficacy, but without them, drug activity may be limited.

This investigation has examined the pharmacokinetic properties of a reductively activated Pt(IV) compound in the multicell layer (MCL) three-dimensional tumour model. This model, unlike the more widely used tumour spheroid system, enabled a quantitative analysis of the distribution and flux parameters for Pt drugs (Hicks et al., 1997). The data verified a mathematical model developed to describe drug pharmacokinetics within solid tissue. Moreover, a novel elemental imaging analysis by synchrotron radiation induced X-ray emission (SRXE) was applied to examine Pt distribution and the degree of intracellular accumulation in MCLs.

**MATERIALS AND METHODS**

**Materials**

Compounds $[^{14}\text{C}]-[\text{PtCl}_2(\text{en})]$ ($[^{14}\text{C}]-\text{Pt}(\text{II}); 34 \text{ Ci/mol}$) (Figure 1B) and $[^{14}\text{C}]-\text{cis,trans-}[\text{PtCl}_2(\text{OH})_2(\text{en})]$ ($[^{14}\text{C}]-\text{Pt}(\text{IV}); 68 \text{ Ci/mol}$) (Figure 1C) were synthesised according to published methods (Hall et al., 2004b). KCl in ddH$_2$O at 0.5 mM concentration and stored in aliquots at −20°C. Twenty-four-well culture plates and Transwel-Col inserts (polyester sidewall, 6.5 mm internal diameter, bovine placental collagen type I- and III-coated polytetrafluoroethylene (PTFE) membrane, 0.33 cm$^2$ surface, 400 nm average pore size) were obtained from Corning Life Sciences (Loughborough, UK), penicillin and streptomycin from Cambrex Bioscience (Verviers, France), spinner flasks were obtained from Techne Ltd (Cambridge, UK). All other cell culture materials were purchased from Invitrogen (Paisley, UK). Agarose was bought from BioWhittaker Biological Applications (Rockland, ME, USA) and Ready Protein$^+$ scintillation liquid from Beckman Coulter Inc. (Fullerton, CA, USA). Hypoxyprobe$^-$-1 kit was purchased from Chemicon Europe Ltd (Chandlers Ford, UK), Brij 35 from Fisher Scientific (Loughborough, UK) and peroxidase blocking agent from DAKO Corporation (Carpinteria, CA, USA). MACH2 horseradish peroxidase-labelled anti-mouse secondary antibody was obtained from Biocare Medical (Concord, CA, USA) and DAB substrate chromogen from DakoCytomation (Ely, UK). Haematoxylin and Aquamount were purchased from BDH Laboratory Supplies (Lutterworth, UK). All other chemicals were from Sigma and at least analytical grade.

**Cell lines and MCL culture**

DLD1 colon carcinoma cells were a kind gift of Dr Roger Phillips (Bradford, UK) and were maintained according to published protocols (Hall et al., 2004b). DLD1 cell monolayers were detached from culture flasks with trypsin/EDTA (Invitrogen) and 3 × 10$^5$ cells were seeded into Transwel-Col inserts. After a few hours the cells settled and the inserts were transferred into spinner flasks (Techne Ltd) with 50 ml RPMI 1640 medium per insert and half of the medium was refreshed every third day.

**Measuring flux of radiolabelled compounds through the MCL system**

Triplicate inserts, with or without MCLs, were transferred into 24-well plates with 1000 μl fresh medium in the wells (Figure 1A). At the beginning of the transport assay the medium in the donor compartment (DC) was replaced with fresh RPMI 1640 medium containing the $[^{14}\text{C}]-$labelled platinum compound. The volume in the DC was 150 and 1000 μl in the RC. Under these conditions, the fluid levels between the receiver compartment (RC) and DC were level and consequently, transport was driven by the concentration gradient. In subsequent experiments, to provide convective force against the concentration gradient–driven diffusion, the volume of the RC was increased to 1500 μl. The reverse gradient was created by increasing the DC volume to 280 μl and keeping the RC at 1000 μl. These two configurations provide ± 3 mm H$_2$O hydrostatic pressure between the two compartments. The RC was not stirred because the flux rates across the membrane were identical with or without stirring (data not shown). The experiment apparatus was kept in the incubator (37°C) and at each time point the insert was moved to a new well. An 800 μl sample was taken from the RC and

![Image](afii9839)

**Figure 1** The MCL system and chemical structures of platinum compounds. (A) Transwel-Col inserts were placed with MCL grown on the PTFE membrane into the well of a 24-well tissue culture plate. The culture medium containing the radiolabelled compounds was added to the DC in variable fluid volumes (I–III) and fluxes were measured by taking samples from the RC. (B and C) The structures of the four $[^{14}\text{C}]-\text{cis-}[\text{PtCl}_2(\text{OH})_2(\text{en})]$ and six-coordinate platinum compounds ($[^{14}\text{C}]-\text{cis,trans-}[\text{PtCl}_2(\text{OH})_2(\text{en})]$. (D) The DLD1 MCL were cultured in spinner flasks for 16 days and stained with the hypoxia probe pimonidazole on a 5 μm paraffin cross-sections (× 10 objective) (for details see Materials and Methods).
the radioactivity at each time point was measured in a Beckman liquid scintillation counter after mixing the sample with 4 ml Ready Protein \(^+\) scintillation liquid.

Non-specific binding of radiolabelled compounds to the transport apparatus can influence the interpretation of transport results. Consequently, non-specific binding to polystyrene surfaces in the RC was determined by measuring the decrease in drug concentration within the compartment following 2 h incubation with \([^{14}\text{C}]\)-Pt complex. The \([^{14}\text{C}]\)-Pt complex was added as a 9 : 1 mixture of non-labelled and radiolabelled complexes in culture medium at the concentration used during the transport assays. The cumulative amount of drug in the RC was corrected for non-specific binding to the RC.

A similar correction was made for drug concentrations in the DC. After completion of transport assays, samples were taken from the DC and the PTFE membranes with the MCL were excised to measure bound radioactivity. In control experiments without MCLs the PFTE membrane was excised. The percentage of added radioactivity to the DC and the PTFE membranes with the MCL were excised to account for non-specific binding to the DC. After completion of transport assays, samples were taken from the DC and the PTFE membrane in the presence or absence of the MCL, the percentage transported to the RC and the percentage decrease in the DC at the end of the transport assay.

**SRIXE of MCL cross-sections**

MCLs were harvested at the end of the transport experiment using the Pt(IV) compound, processed as described (Modok et al, 2006), and 20 μm sections were cut from the paraffin blocks. The sections were mounted on Formvar-coated plastic specimen holders. Micro-SRIXE experiments were performed on beamline ID22 at the European Synchrotron Radiation Facility (ESRF; Grenoble, France). Fluorescence spectra were collected using a single element Si(Li) detector, placed approximately 20 mm from the sample. Two-dimensional maps corresponding to the integrated Kα fluorescence signal of an element of interest were collected by scanning the sample. The elements analysed were P, S, Cl, K, Ca, Fe, Ni, Cu, Zn, and Pt which was analysed using the Lα and Lβ fluorescence lines. Elemental contents were quantified by comparison to SRM 1832 and 1833, and then converted to \([^{14}\text{C}]\)-Pt complex bound to the DC was determined by subtracting MCLs the PFTE membrane was excised. The percentage of added concentration within the compartment following 2 h incubation results. Consequently, non-specific binding to polystyrene surfaces transport apparatus can influence the interpretation of transport results. Moreover, the flux through the membrane equals the change of concentration of molecules in the membrane surface area (A, cm\(^2\)) and the concentration gradient across the membrane. Furthermore, the flux through the membrane equals the change of concentration of molecules in the RC, hence we get

\[
\frac{d}{dt}C_k(t) = \frac{Ak}{V_R} (C_D(t) - C_k(t))
\]

where \(k\) is the mass transfer coefficient (cm s\(^{-1}\)). \(C_D\) can be eliminated using Eq. 1 and then Eq. 2 solved to give

\[
C_k(t) = \frac{V_R C_D}{V_R + V_D} \left(1 - e^{-\frac{d}{x} \left(\frac{V_R}{V_R + V_D}\right)^{\frac{1}{n+1}}}ight)
\]

The fitted parameter was \(k\) and the relative porosity of the membrane for the compounds (impedance, \(\psi\)) was determined according to

\[
k = \frac{D_1}{\Delta x}
\]

where \(D_1\) is the diffusion coefficient of the compound in medium (cm\(^2\) s\(^{-1}\)) and \(\Delta x\) is the measured thickness of the membrane (cm).

**Mathematical model to describe drug transport through the MCL**

The transport of radiolabelled compounds through the MCL was modelled as Fickian diffusion. The insert with the MCL can be seen as an anisotropic cylinder which has its axis along the direction x (Figure 1A) and is bounded by planes perpendicular to x and the problem of diffusion into it reduces to the corresponding problem in an isotropic cylinder provided \(D_z = D_x\) where \(D_z\) and \(D_x\) are diffusion constants in the other two directions of space (Dolman et al, 2002). As the concentration only varies along the x axis, we can describe the diffusion of the drug in the MCL by

\[
\frac{\partial C}{\partial t} = \frac{\partial}{\partial x} \left(D_m \frac{\partial C}{\partial x}\right)
\]
where \( D_M \) is the diffusion coefficient of the compound in the MCL (cm\(^2\) s\(^{-1}\)) and \( x \) is the distance from the top free surface of the MCL (cm). \( \Gamma \) and \( g \) (s\(^{-1}\)) is the rate of cellular uptake of the compound. \( D_M \) can be defined by the impedance of MCL \( (\Gamma) \) and the diffusivity of the compound in medium \( (D_1, \text{cm}^2 \text{s}^{-1}) \) as

\[
D_M = \Gamma \ast D_1
\]  

The boundary conditions were at \( x = 0 C(0,t) = C_D(t) \), where the concentration in top compartment is calculated from the mass balance by considering the flux of molecules that enters the MCL, i.e.,

\[
\frac{d}{dt} C_D(t) = \frac{AD}{V_D} \frac{\partial C}{\partial x} \bigg|_{x=0}
\]  

The continuity of the flux at the interface between the MCL and the membrane gives us another boundary condition at

\[
x = x_M - D_M \frac{\partial}{\partial x} C(x_M, t) = k(C(x_M, t) - C_R(t))
\]

where \( x_M \) is the thickness of the MCL. Furthermore, the governing equation for the drug concentration in the RC \( (C_R(t)) \) is at

\[
x = x_M + \Delta x \frac{d}{dt} C_R(t) = \frac{A_k}{V_k} C(x_M, t) - C_R(t)
\]

Eqs. 5–9 are coupled partial differential equations, which were used to write a program in Matlab to simulate the experimental situation with initial conditions \( C = 0 \) at \( 0 < x \leq x_M \) and \( C_R(0) = 0 \) to calculate \( \Gamma, D_M \) and \( g \).

**Data analysis**

Data were presented as either mean ± s.d. or mean ± s.e.m. The data were analysed with two-tailed \( t \)-test using GraphPad Prism 3.2 software and \( P < 0.05 \) was considered statistically significant. Diffusivity and the rate of cellular uptake were determined using programs based on the mathematical models described above and written in Matlab 7.0.1 software.

**RESULTS**

**Growth and histological characterisation of MCL**

Multicell layers were cultured from DLD1 colon adenocarcinoma cells on collagen-coated PTFE membranes (Figure 1), which were floated in spinner flasks to provide optimised conditions for growth. The MCL were used on the seventh day of culture and displayed a tissue depth of 131 ± 10 μm. A pimonidazole-based assay was used to detect hypoxia in the MCL and demonstrate tissue morphology (Figure 1D). Full morphological characterisation of this tissue model was described previously (Modok et al., 2006). The MCL showed pimonidazole staining towards the upper surface of the tissue, which is indicative of hypoxia. This localised hypoxia may be explained by the high demand for oxygen, which results from such a densely packed avascular population of cells, akin to that in tumour spheroids. This suggests that the MCL model is a good representation of solid tumour architecture and the associated microenvironment (Modok et al., 2006).

**Diffusivity and cellular uptake rate of \([^{14}\text{C}]\text{-Pt(II)}\) and \([^{14}\text{C}]\text{-Pt(IV)}\) compounds in MCL**

The transport of the compounds through the PTFE membrane with or without the MCL was measured by loading the radiolabelled drugs to the DC and measuring the radioactivity appearing in the RC over time (Figure 1A). Initially, 150 and 1000 μl volumes of culture medium were loaded to the DC and RC respectively, to maintain an equivalent fluid level and therefore avoid hydrostatic pressure-driven convective transport. The non-specific binding of the compounds to the plastic surfaces in DC and RC was determined to improve the accuracy of the subsequent quantitative analyses (Table 1). For example, the fraction bound to the DC reduces the effective concentration gradient, whereas the fraction bound to the RC falsely reduces the flux rate. The fractions bound to the DC and to the RC were used to correct the starting drug concentration and the concentration of the drug transported, respectively. The cumulative concentration of \([^{14}\text{C}]\text{-Pt(II)}\) and \([^{14}\text{C}]\text{-Pt(IV)}\) were expressed as a percentage of the initial drug concentration in the DC.

Figure 2 shows the cumulative amounts of Pt complexes appearing in the DC of the MCL apparatus. Data are provided for fluxes in the presence or absence of the MCL tissue overlaid on the PTFE membrane. As expected, the rate and extent of flux was greater for both drugs in the absence of the MCL. The data in Figure 2 clearly demonstrates that there was no difference between \([^{14}\text{C}]\text{-Pt(IV)}\) and \([^{14}\text{C}]\text{-Pt(II)}\) with respect to their cumulative appearance in the DC. Mathematical modelling without a cellular uptake parameter did not fit the data obtained in the presence of an MCL but was an accurate reflection for passage across the PTFE membrane alone. The mathematical model comprising an uptake coefficient was used to quantify flux of the compounds through the solid tumour model and the data are summarised in Table 2. The mass transfer coefficients \( k \) and relative porosity \( \phi \) values

### Table 1 Binding of the radiolabelled compounds in the MCL system

| Membrane   | \([^{14}\text{C}]\text{-Pt(II)}\) | \([^{14}\text{C}]\text{-Pt(IV)}\) | \([^{14}\text{C}]\text{-Pt(II)}\) | \([^{14}\text{C}]\text{-Pt(IV)}\) |
|------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Added to DC | 100                           | 100                           | 100                           | 100                           |
| Decrease in DC | 46.3 ± 2.6, n = 3           | 43.06 ± 2.6, n = 3           | 17.0 ± 3.6, n = 12           | 5.4 ± 1.7, n = 9              |
| Membrane+MCL | 0.1 ± 0.1, n = 3           | 0.3 ± 0.1, n = 5             | 0.7 ± 0.3*, n = 6            | 0.5 ± 0.2*, n = 9             |
| Transported | 27.8 ± 5.0, n = 3           | 28.6 ± 3.5, n = 3           | 5.3 ± 0.8, n = 12            | 5.3 ± 0.5, n = 12             |
| Bound to RC | 12.8 ± 0.4, n = 3           | 16.6 ± 1.2, n = 3           | 12.8 ± 0.4, n = 3           | 16.6 ± 1.2, n = 3             |
| Bound to DC | 18.5 ± 7.0, n = 3           | 13.9 ± 5.6, n = 3           | 10.1 ± 2.8, n = 6           | 10.5 ± 4.3, n = 9             |

Abbreviations: DC, donor chamber; en, ethane-1,2-diamine; MCL, multicell layer; \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\), \([^{14}\text{C}]\text{-Pt(II)}\). The percentage bound to the DC was calculated by subtracting the percentage bound to membrane + MCL and the percentage transported to the receiver chamber RC from the percentage decrease in the DC at the end of the transport assay. These values and the non-specific binding of radiolabelled compounds to the RC were measured as it is described in Materials and Methods. *Statistically significant \((P<0.05)\) accumulation of the Pt compounds in the MCL compared to the PTFE membrane alone.
of the two platinum compounds through MCLs were indistinguishable. The coefficient of diffusion was ascertained for the Pt(IV) and Pt(II) drugs through the MCL model utilizing the parameters of mass transfer coefficient (k), MCL thickness ($x_1$), diffusivity in the medium ($D_1$) and initial drug concentration ($C_0$). The calculated diffusion coefficients ($D_{MCL}$) and cellular uptake (g) rates were not different for the two platinum compounds (Table 2), reflecting similar flux parameters for the two classes of platinum complex in a solid tissue.

**Cellular accumulation of [14C]-Pt in the MCL; SRIXE analysis**

Accumulation of Pt compounds in the MCL was determined by measuring the radioactivity retained in the PTFE membrane + MCL after the transport assays. As shown in Table 1, the radioactivity associated with the membrane was higher in the presence of the MCL, although there was no significant difference between [14C]-Pt(II) compared to [14C]-Pt(IV). Data from the mathematical modelling above suggested a significant degree of uptake for Pt drugs within the MCL tissue. Image analysis using SRIXE was used to confirm this suggestion and the technique enabled an extensive elemental analysis of the MCL tissue. The data show that the tissue that had been exposed to the [14C]-Pt(IV) drug was associated with an incorporated Pt signal (Figure 3). This confirmed the experimental and mathematical modelling data and demonstrates that flux through solid tissue is associated with a non-negligible degree of Pt drug uptake into cells. Quantitation of the Pt signal across the tissue revealed a greater Pt(IV) complex concentration at the upper surface (i.e. facing the DC) (Figure 4).

**The effect of hydrostatic pressure on the flux of [14C]-Pt(IV) through MCL**

The six-coordinate Pt(IV) compounds have been proposed to display a greater likelihood of reduction to the active Pt(II) species in the hostile intratumour microenvironment. Consequently, ensuring sufficient penetration of Pt(IV) drugs to the deeper layers of a tumour remains a key issue. One proposed way of

**Table 2 Physical and chemical parameters of radiolabelled platinum compounds**

|                  | [14C]-Pt(II) | [14C]-Pt(IV) |
|------------------|-------------|-------------|
| Molecular weight | 325         | 359         |
| Molecular radius (nm) | 0.4 a | 0.4 a |
| Diffusion coefficient in medium ($D_1$, x 10^{-6} cm$^2$s$^{-1}$) | 8.2 b | 8.2 b |
| Mass transfer coefficient (k, x 10^{-5} cm$^2$s$^{-1}$) | 2.7 ± 0.6, n = 3 | 2.5 ± 0.4, n = 3 |
| Relative porosity of membrane ($\psi$, x 10^{-2}) | 1.2 ± 0.3, n = 3 | 1.2 ± 0.2, n = 3 |
| Impedance of MCL ($\Gamma$, x 10^{-12}) | 2.1 ± 0.3, n = 3 | 2.2 ± 0.4, n = 4 |
| Diffusion coefficient in MCL ($D_{MCL}$, x 10^{-10} cm$^2$s$^{-1}$) | 17.5 ± 2.6, n = 3 | 317.8 ± 3.1, n = 4 |
| Uptake rate in MCL (g, x 10^{-7} min$^{-1}$) | 17.7 ± 5.5, n = 3 | 316.2 ± 5.3, n = 4 |

*aThe molecular radius of Pt(II) and Pt(IV) was estimated based on the size of carboplatin (8 x 3 x 3 Å) and cisplatin (5 x 3 x 1.5 Å) as measured in MDLChime.

bThe diffusion coefficient of platinum compounds in culture medium was calculated according to the Stokes–Einstein equation using the molecular radius.

**Figure 3** The cellular accumulation of [14C]-Pt(IV) in MCL: SRIXE analysis. After the transport assay the MCL was processed, embedded in wax and 20 μm sections through the MCL were imaged in a synchrotron x-ray beam using SRIXE. Fitted images of the elemental distributions in segments of a Pt(IV)-treated MCL and a control non-treated MCL are shown. The scale on the axes represents the number of pixels, where each pixel is 3 x 2 μm (horizontal x vertical). The images show relative elemental concentrations, using the colour scale shown, which ranges from blue, representing low levels, to red, representing high elemental levels. The arrowheads indicate the position of the PTFE membrane supporting the MCL (shown in Figure 1D).
improving penetration is to increase the hydrostatic pressure to counteract the increased interstitial pressure generated in tumours. The MCL system (Figure 1) provides a convenient means to investigate whether hydrostatic pressure can modulate the flux of $^{14}$C-Pt(IV) through solid tumour tissue. Hydrostatic pressure may be varied by simply altering the fluid levels in the DC and RC and was applied in both the same and opposite directions to the concentration gradient of the MCL system. Figure 5 shows the cumulative amount of $^{14}$C-Pt(IV) that had penetrated through the MCL in to the lower RC, relative to the amount of drug added originally to the DC. At a hydrostatic pressure of $-3\text{ mm H}_2\text{O}$ (i.e. against concentration gradient), the amount of penetration was reduced from $0.82 \pm 0.01$ to $0.73 \pm 0.01\%$. In contrast, as the hydrostatic pressure was increased to $+4\text{ mm H}_2\text{O}$ (i.e. along the concentration gradient), the flux of $^{14}$C-Pt(IV) was increased to $1.06 \pm 0.08\%$. The data therefore indicate that even a relatively minor hydrostatic pressure gradient was capable of a significant influence on the flux of $^{14}$C-Pt(IV) through the MCL tumour model.

**DISCUSSION**

Platinum-based chemotherapy remains a vital component of many oncological treatment strategies. As with the majority of ‘genotoxic’ anticancer drugs, the Pt complexes are beset by problems with toxicity, resistance and poor pharmacokinetic properties. A great deal of effort has been placed in generating more potent and selective derivatives of conventional Pt(II) drugs such as cisplatin. In particular, the six-coordinate Pt(IV) complexes offer several advantages including lower reactivity and a greater potential for introducing hydrophobicity to facilitate cellular uptake. There is little information available on either class of Pt drug relating to their behaviour in solid tumour tissue. This study has utilised a solid tumour model to quantify flux behaviour of Pt(II) and Pt(IV) complexes. Flux through the solid tumour model was associated with significant cellular accumulation and was sensitive to changes in the applied hydrostatic pressure.

The MCL system is widely accepted as a good model of solid tumour tissue, in particular the non-vascularised regions or nodules. The colon cancer MCLs described previously (Modok et al, 2006), display heterogeneity of cell status (i.e. proliferating and quiescent) in addition to having a high cell density and localised regions of hypoxia. Both of the compounds tested were able to completely penetrate the MCL tissue with the diffusion coefficients of $17.5 \pm 2.6 \times 10^{-8} \text{ cm}^2 \text{s}^{-1}$ for the Pt(II) and $17.8 \pm 3.1 \times 10^{-8} \text{ cm}^2 \text{s}^{-1}$ for the Pt(IV) complex. These rates of diffusion were almost 10-fold higher than that reported for the hydrophobic anticancer drug vinblastine $(1.88 \pm 0.21 \times 10^{-8} \text{ cm}^2 \text{s}^{-1})$ and fourfold higher than that of the highly hydrophilic sucrose $(4.22 \pm 0.89 \times 10^{-8} \text{ cm}^2 \text{s}^{-1})$ (Modok et al, 2006). A similar rapid flux (i.e. % drug min$^{-1}$) of cisplatin compared to vinblastine has been reported in MCL comprising bladder cancer cells, whereas etoposide, gemcitabine and paclitaxel displayed faster rates of flux (Tannock et al, 2002). A major advantage of the current approach is the ability to calculate the actual diffusion coefficients, which may be directly applied to the prediction of tissue drug concentrations; for example, as a function of the distance from a blood vessel (Modok et al, 2006). This rapid flux across the MCL should be considered a positive feature for such compounds. A considerable emphasis in the design of platinum drugs has been placed on developing lipophilic drugs that can assist in circumventing diminished cisplatin accumulation in resistant cell lines; however, it may be that defeating unicellular resistance may come at the expense of tissue penetration, and therefore create the problem of multicellular resistance. It seems that hydrophobic drugs such as those examined here allow for excellent tissue penetration. If this feature can be coupled with a more readily reducible Pt(IV) compound (the Pt(IV) compound studied here is the most inert in a series studied), a drug with good penetration and cytotoxic potential may be arrived at.

The Pt(IV) compound used in this study has been shown to display lower cellular accumulation in well-oxygenated monolayers of cancer cells (Hall et al, 2004a) and lower serum protein binding compared to the Pt(II) parental derivative (Dolman et al, 2002). Therefore Pt(IV) would be expected to display higher flux rates across MCL than Pt(II); unless the compound is rapidly converted into the parental Pt(II) version. The latter is highly unlikely given that in cells treated with platinum(IV) complexes, 50% of a trans-Pt(IV) dihydroxo complex remained oxidised 2 h after incubation, which corresponds to the longest time point in these experiments (Hall et al, 2003). The two Pt compounds had undistinguishable flux kinetics across the MCL and in both cases the mathematical model required the inclusion of a specific component to account for cellular uptake within the tissue. Similarly, the calculated diffusion constants and cellular uptake rates also failed to detect any pharmacokinetic differences between the two compounds. What is the explanation for the similar rates of flux through the solid tissue given the physico-chemical differences between Pt(II) and Pt(IV) species? Certainly neither compound has reacted
movement in cancer tissue is largely limited to diffusion (Heldin et al., 2004). Restoring the physiological filtration by increasing the hydrostatic pressure is a possible option to improve drug delivery to deeper layers of cancer cells within the three-dimensional solid tumour mass. Our results show that because the flux of the two compounds was sensitive to hydrostatic pressure the convection could potentially increase the penetration of tumour mass by platinum drugs. This principle, known as convection enhanced delivery (CED), has actually been utilised to treat intracranial tumours where the confined space further increases the effects of interstitial pressure (Heldin et al., 2004). Cisplatin is expected to be useful via local drug delivery (Newton, 2005) in intracranial tumours due to its reported rapid flux rate, although an enhancement by CED has not yet been examined.

In conclusion, the data from this investigation provide hitherto unknown pharmacokinetic properties for two platinum compounds; namely the absolute diffusion coefficient through solid tumour tissue. Moreover, both experimental and mathematical models provide a convenient means to facilitate the in vitro development of novel six-coordinate platinum compounds; particularly to enable a bridge between observations in simple cell monolayer systems to the complexities associated with poorly vascularised hypoxic tumours in vivo.

ACKNOWLEDGEMENTS

This investigation was generously supported by a Cancer Research UK Program Grant (C362/A913) for which RC was the principal investigator. TR funded by Royal Society University Research Fellowship.

REFERENCES

Brunetti A, del Rio MS, Golosio B, Simionovici A, Somogyi A (2004) A library for X-ray matter interaction cross sections for X-ray fluorescence applications. Spectrochim Acta B 59: 1725 – 1731

Dolman RC, Deacon GB, Hambley TW (2002) Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J Inorg Biochem 88: 260 – 267

Hall MD, Amjadi S, Zhang M, Beale PJ, Hambley TW (2004a) The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. J Inorg Biochem 98: 1614 – 1624

Hall MD, Foran G, Zhang M, Beale PJ, Hambley TW (2003) XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents. J Am Chem Soc 125: 7524 – 7525

Hall MD, Martin C, Ferguson DJP, Phillips RM, Hambley TW, Callaghan R (2004b) Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochim Pharmacol 67: 17 – 30

Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 4: 806 – 813

Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR (1997) An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer 76: 894 – 903

Holzer AK, Katano K, Klopemp LW, Howell SB (2004) Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells. Clin Cancer Res 10: 6744 – 6749

Ilinsky P, Lai B, Cai Z, Yun W, Legnini D, Talatozo C, Cholowa M, Webster EL, Deacon GB, Rainone S, Phillips DR, Stampf AP (2003) The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe. Cancer Res 63: 1776 – 1779

Kartalou M, Essigmann JM (2001) Recognition of cisplatin adducts by cellular proteins. Mutat Res 478: 1 – 21

Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB (2004) Confocal Microscopic Analysis of the Interaction between Cisplatin and the Copper Transporter ATP7B in Human Ovarian Carcinoma Cells. Clin Cancer Res 10: 4578 – 4588

Lindauer E, Holzer E (1996) Cellular distribution and cellular reactivity of platinum (II) complexes. Biochem Pharmacol 52: 7 – 14

Lottner C, Kneuchel R, Bernhardt G, Brunner H (2004) Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells. Cancer Lett 215: 167 – 177

Mellor HR, Snelling S, Hall MD, Modok S, Jaffar M, Hambley TW, Callaghan R (2005) The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. Biochem Pharmacol 70: 1137 – 1146

Modok S, Hyde P, Mellor HR, Roose T, Callaghan R (2006) Diffusivity and distribution of vinblastine in three-dimensional tumour tissue: Experimental and mathematical modelling. Eur J Cancer 42: 2404 – 2413

Newton HB (2005) Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol 6: 519 – 530

Nishikawa K, Newman RA, Murray L, Khokhar AR, Rosenblum MG (1990) Detection of cellular platinum using the monoclonal antibody 1G1. Mol Biother 2: 235 – 241

Siddik ZH (2002) Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 112: 263 – 284

Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8: 878 – 884

Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307 – 320